|Articles|September 1, 2000

Implementing Optimal Guidelines for Growth Hormone Use in a Managed Care Population
Volume 6
Issue 15 Suppl

CME / CPE / CCMCE Quiz

Download PDF: CME / CPE / CCMCE Quiz

Articles in this issue

almost 26 years ago

Article

Participating Faculty

almost 26 years ago

Article

Introduction

almost 26 years ago

Article

Growth Hormone Use in Pediatric Growth Hormone Deficiency and Other Pediatric Growth Disorders

almost 26 years ago

Article

Clinical and Reimbursement Issues on Growth Hormone Use in Adults

almost 26 years ago

Article

Growth Hormone Use in Transitioning Patients -- Clinician and Payer Concerns

almost 26 years ago

Article

Recommendations on Improving the Use of and Managed Care Review Process of Growth Hormone Therapy

almost 26 years ago

Article

Clinician and Payer Issues in Managing Growth Hormone Deficiency

almost 26 years ago

Article

Selected Abstracts

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

CME / CPE / CCMCE Quiz

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Approves First Autoinjector for At-Home IV-Equivalent Diuresis

Diagnosing Alzheimer's Disease Agitation: Triggers, Care Specialties, and the Role of Primary Care

Defining Alzheimer's Disease Agitation: Diagnostic Criteria, Symptoms, and Disease Course

Small Workflow Changes Close Big Gaps in CKM Screening

Pirtobrutinib Plus Venetoclax-Rituximab Cuts CLL Progression 45%